Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01316432 · ClinicalTrials.gov registry record · Phase 1
PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients
A Phase 1 study of Heart Failure and Chronic Heart Failure, sponsored by Nile Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 5
- Study locations
NCT01316432 is a Phase 1 study of Heart Failure and Chronic Heart Failure that has completed, run by Nile Therapeutics. The registered enrollment target is 58 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01316432, a Phase 1 study of Heart Failure and Chronic Heart Failure, has completed, sponsored by Nile Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purposed of the study is to evaluate the pharmacokinetics (PK) response of continuous subcutaneous (SQ) infusion of cenderitide, as compared with a single SQ bolus.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Cenderitide
Study Locations (5)
California
- Orange County Research Center - Tustin
Florida
- Jacksonville Center for Clinical Research - Jacksonville
Kansas
- Analab Clinical Research, Inc. - Lenexa
Louisiana
- Benchmark Research - Metairie
Minnesota
- Hennepin County Medical Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01316432
The ClinicalTrials.gov registry entry for NCT01316432 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The listed sponsor is Nile Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01316432 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT01316432 about?
NCT01316432 is a clinical study titled "PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients". The purposed of the study is to evaluate the pharmacokinetics (PK) response of continuous subcutaneous (SQ) infusion of cenderitide, as compared with a single SQ bolus.
What is the current status of trial NCT01316432?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2011-05. Estimated completion is 2011-11.
What conditions does trial NCT01316432 study?
This clinical trial studies the following conditions: Heart Failure, Chronic Heart Failure, CHF, ADHF.
What interventions are being tested in trial NCT01316432?
The interventions under investigation include: Placebo (OTHER), Cenderitide (DRUG).
Who is sponsoring clinical trial NCT01316432?
This trial is sponsored by Nile Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01316432 being conducted?
This trial has 5 study locations across California, Florida, Kansas, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Semaglutide Therapy in Heart Failure Patients
RECRUITING · Phase 1
-
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
RECRUITING · Phase 1
-
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
RECRUITING · Phase 1
-
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.